Oxurion Announces Upcoming Presentation on THR-149 Phase 2 Clinical Trial (“KALAHARI”) at the Angiogenesis, Exudation, and Degeneration 2022 Conference
Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in vascular retinal disorders, will be presenting data from Part A of its two-part Phase 2 Clinical Trial (“KALAHARI”) assessing THR-149 for treatment of diabetic macular edema (DME) at the upcoming Angiogenesis, Exudations, and Degeneration 2022 Meeting being held virtually on February 11-12th. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the 40-50% of DME patients showing suboptimal response to anti-VEGF therapy.
Details of the presentation:
TITLE: Phase 2 Results of THR-149 in Patients with DME: KALAHARI Study Part A
PRESENTER: Arshad M. Khanani, MD, MA, Managing Partner, Director of Clinical Research, Director of Fellowship – Sierra Eye Associates; Clinical Associate Professor at the University of Nevada, Reno, NV
PRESENTATION DATE AND TIME: Saturday, February 12, 2022, 12:00 pm ET.